Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.
Silbermann RW, Schmidt TM, Bal S, Dhakal B, Dholaria B, Biltibo E, Chhabra S, Giri S, Godby KN, Gowda S, Medvedova E, Cornell RF, Callander NS, Costa LJ. Silbermann RW, et al. Among authors: dholaria b. EJHaem. 2023 Jun 22;4(3):775-778. doi: 10.1002/jha2.736. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601885 Free PMC article.
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy.
Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M. Kanate AS, et al. Among authors: dholaria b. Transplant Cell Ther. 2023 Oct;29(10):594-597. doi: 10.1016/j.jtct.2023.07.002. Epub 2023 Jul 6. Transplant Cell Ther. 2023. PMID: 37422194 Free article.
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD Jr, Hamadani M. Oluwole OO, et al. Among authors: dholaria b. Transplant Cell Ther. 2024 Feb;30(2):131-142. doi: 10.1016/j.jtct.2023.11.008. Epub 2023 Nov 10. Transplant Cell Ther. 2024. PMID: 37951502 Review.
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Costa LJ, et al. Among authors: dholaria br. Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27. Lancet Haematol. 2023. PMID: 37776872 Clinical Trial.
Emerging therapeutic agents for lung cancer.
Dholaria B, Hammond W, Shreders A, Lou Y. Dholaria B, et al. J Hematol Oncol. 2016 Dec 9;9(1):138. doi: 10.1186/s13045-016-0365-z. J Hematol Oncol. 2016. PMID: 27938382 Free PMC article. Review.
Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Marin-Acevedo JA, et al. Among authors: dholaria b. J Hematol Oncol. 2018 Jan 12;11(1):8. doi: 10.1186/s13045-017-0552-6. J Hematol Oncol. 2018. PMID: 29329556 Free PMC article. Review.
100 results